Servatus strengthens board with new appointment

Latest News

Australian biopharmaceutical company Servatus has announced the appointment of Dr Uwe Buecheler to its board as a non-executive director.

Dr Buecheler is a leading molecular biologist with more than 30 years of biopharmaceutical experience at Boehringer Ingelheim. 

Boehringer Ingelheim is one of the world's leading pharmaceutical companies and the largest private pharmaceutical company.

Servatus said Dr Buecheler’s appointment brings significant commercial and scientific experience to its board at a time when it is bolstering its Australian research and development capabilities for market-leading live biotherapeutic programs, including clinical trials for IBS-C, insomnia, rheumatoid arthritis and other health problems associated with the gut-microbiome-brain axis.

Servatus CEO Dr Wayne Finlayson said, “We are thrilled to have Dr Uwe Buecheler join our Board as Non-Executive Director. Uwe brings extensive scientific and commercial leadership as well as invaluable experience in developing global biopharmaceutical operations. His appointment will significantly strengthen our Board capabilities and further complement the high calibre team Servatus has drawn from around the world as we look to advance development of our market-leading biotherapeutics programs. We hope to leverage Uwe’s vast knowledge and experience gained throughout his many years at Boehringer Ingelheim, one of the world’s top pharmaceutical companies, while expanding Servatus’ core business units over the next three years.”

Dr Buecheler added, “I am delighted to join Servatus’ Board during an exciting period of growth for the Company. Servatus is backed by a highly experienced and credible team that is at the forefront of microbial biotherapeutics and it is an honour for me to take up this opportunity to help contribute to the growth of Servatus during a pivotal time in the company’s history. I look forward to delivering on our objectives to maximise the global expansion capabilities of this leading business over the next three years and beyond.”